- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
A Study about Escitalopram Versus Citalopram in the Treatment of Depressive Disorders | ||
| Mosul Journal of Nursing | ||
| Article 3, Volume 3, Issue 2, 2015, Pages 68-72 PDF (618.05 K) | ||
| Document Type: Original Articles | ||
| DOI: 10.33899/mjn.2019.160023 | ||
| Authors | ||
| Jasim M. Shindi1; Ali Talib Gallib2 | ||
| 1Escitalopram, citalopram, depressive disorders (DD), efficacy. | ||
| 2BSc. Pharmacy/ Kirkuk General Hospital-Kirkuk. Iraq/ E-mail: [email protected] | ||
| Abstract | ||
| Background and aim: To compare the therapeutic efficacy , time onset of action, and patient compliance of escitalopram versus citalopram in the treatment of depressive disorders (DD) in Kirkuk City _Iraq Materials and Method: 100 outpatients complaining of (DD ) consulting psychiatric unit in Azadi teaching hospital were randomly categorized in to two therapeutic groups with escitalopram and citalopram. A structural interview form (questionnaire) containing socio demographic data and assessing 8 target symptom of depression according to (DSM-IV) derived from a preliminary pilot study in the same unit to reveal most common presentations of (DD ) in Azadi teaching hospital, psychiatric unit inpatients in Kirkuk city , these symptoms were assessed according to a 4 degree scale (0_3 ) according to clinical interview by consultant psychiatrist on call, patients were followed up for 12 weeks. Results: The majority of the study sample were aged group was between (30-39) years, the male formed (38-40%), while the female (60-62%) in each group, (54-58%) of them were married, (48%) of the escitalopram group had moderate economic level while (44%) the of the citalopram group had low economic level, Muslim religion constitute (100%), and the no history of medical illness formed (80-88%). Conclusion: The our study concluded statistically significant superiority of escitalopram versus citalopram regarding the effectiveness, early symptom relief, patient compliance and significant change in dose score, After 12 weeks of treatment with fixed dose of 20 mg of escitalopram and 20 _40 mg. Recommendations: Further comparative studies between escitalopram andcitalopram are recommended with large sample sizes and longer duration of follow up to cover all stages of treatment of depressive disorder (DD) symptom. | ||
| Keywords | ||
| Escitalopram; Citalopram; depressive disorders (DD); efficacy | ||
| References | ||
|
Bertam, G.; katzung, MD.; Susan, B. Anthony J. trevor. (2011). Basic andclinical pharmacology 12 Edition.
British National Forulary 62. (2011). Chapter 4. Central nervous system. P.p. 235-248.
Burke, WJ.; Gergel, I.; Bose, A. (2002). Fixed-dose trial of the single isomer SSRI,escitalopram in depressed outpatients. Journal of clinical psychiatry.
FDA center for Drug Evaluation and Research. (2009). Review and evaluation of clinical data for application. 21-323.
Gorman, J.; Korotzer, A.; Su, G.; (2002). Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo_ controlled trials. CNS. 7:40_44.
Kaplan and Sadock. (1985). A comprehensive textbook of psychiatry Lippincott Williams Wilkins. (5th Edition).
Kasper, S.; Stein, DJ.; Loft, H.; Nil, R. (2005). Escitalopram in the treatment of social anxiety disorder: Randomized, placebo_ controlled, flexible _dosage study. The British Journal of psychiatry :the journal of mental science. 186 (3). 222-6.
Kirino, E. (2012). Escitalopram for the management of major depressive disorder : a review of its efficacy ,safety, and patient acceptability. 6:853_61.doi:10.214 7 :PPA ,S22495..
Mathers, CD.; and Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLos Med. 3 (11).
MHRA drug safety update. (2011). Citalopram and escitalopram: QT interval prolongation new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings.
Patten; SB.; Kennedy, SH.; Lam R W. (2009). Canadian network for mood and anxiety Treatments (CANMAT) clinical Guidelines for the Management of Major Depressive Disorder in Adults. I Classification, burden and principles of management. J Affect Disorder.117 SUPPI,1s5.14.
UIIa, Lepola; Alan,Wade.; and Henning, Friis Andersen. (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? Apooled analysis of two positive placebo _controlled studies in major depressive disorder. International Clinical psychopharma. 19:149 _155.
Valery,Y.;Yevtushenko,A.; Belous, Yevgenia G.; Yevtushenko, Sergei E.; Gusinin, Oleg J.; Buzik, MD.; and Tatiana V. (2007). Efficacy and Tolerability of Escitalopram Versus Citalopram Major Depressive Disorder:A 6 _Week, Multicenter, Prospective, Randomized, Double-blind, Active _Controlled Study in Adult Outpatients .Clinical Therapeutics. Vol (29).
Van, Gorp F.; Whyte Im.; Isbister gk.(2009). clinical and ECG effects of escitalopram overdose Ann. Emerg Med.54:404_408. | ||
|
Statistics Article View: 883 PDF Download: 819 |
||